Schonfeld Strategic Advisors LLC Satsuma Pharmaceuticals, Inc. Transaction History

Schonfeld Strategic Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $419 - $795	-100 Reduced 0.88%	11,300 $68,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $26,159 - $43,430	-10,100 Reduced 46.98%	11,400 $47,000
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $28,350 - $39,900	7,500 Added 53.57%	21,500 $81,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $830 - $1,248	-200 Reduced 1.41%	14,000 $63,000
Q3 2021 Nov 16, 2021	BUY	$4.54 - $7.17 $64,468 - $101,814	14,200 New	14,200 $67,000
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $69,120 - $104,400	-14,400 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.57 - $7.18 $5,484 - $8,616	-1,200 Reduced 7.69%	14,400 $86,000
Q4 2020 Feb 16, 2021	BUY	$3.56 - $5.09 $55,536 - $79,404	15,600 New	15,600 $72,000
Q3 2020 Nov 16, 2020	SELL	$3.85 - $28.47 $42,350 - $313,170	-11,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $176,110 - $381,590	11,000 New	11,000 $317,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.